Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. The National Comprehensive Cancer Network (NCCN) guidelines for detection, prevention, & risk reduction (2019). Breast Cancer Risk Reduction. Version 1
2. Bo Pan, Ying Xu, Yi-Dong Zhou, Ru Yao, Huan-Wen Wu, Qing-Li Zhu, Chang-Jun Wang, Feng Mao, Yan Lin, Song-Jie Shen, Qiang Sun. The prognostic comparison among unilateral, bilateral, synchronous bilateral, and metachronous bilateral breast cancer: a meta-analysis of studies from the recent decade (2008–2018) (2019). Cancer Med Jun;8(6):2908–2918. https://doi.org/10.1002/cam4.2198. Epub 2019 Apr 30. https://doi.org/10.1002/cam4.2198
3. Jobsen JJ, van der Palen J, Ong F, Riemersma S, Struikmans H.Bilateral breast cancer, synchronous and metachronous; differences and outcome (2015). Breast Cancer Res Treat Sep;153(2):277–83. https://doi.org/10.1007/s10549-015-3538-5. Epub 2015 Aug 13.PMID: 26268697
4. Giacomina Megaro, Luigi Rossi, Serena Ceddia, Marcela Sinjari, Adele Mannino, Elisa Gozzi, Antonella Cosimati, Martina Brandi, Victoria Bitca, Ilaria Toscani, Giuseppe Cimino, Silverio Tomao Synchronous and metachronous metastatic breast cancer, with different histology and opposite ımmunophenotype, treated with combination of chemotherapy, anti-Her2, and endocrine therapy: a case report (2020). Case Rep Oncol May 13;13(2):544–549. https://doi.org/10.1159/000507433. eCollection May-Aug 2020.
5. Danforth DN. Risk assessment for sporadic breast cancer: the need for a molecular profile (2018). Clin Surg 3: 1921
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献